Reference is made to the stock exchange announcement made by Lifecare ASA (the
"Company") earlier today, 25 September 2024, regarding the re-purchase by the
Company of up to 30,000 shares and up to 7,500 warrants in the Company in
connection with the contemplated 13:1 consolidation of the Company's shares
and warrants.

The Company has now completed the re-purchase of 30,000 shares in the Company
at an average price of NOK 1.664873 per share, and the re-purchase of 7,500
warrants in the Company at an average price of NOK 0.415 per warrant. The
purchases were carried out as ordinary trades in the market.

This information is subject to disclosure requirements pursuant to the
Norwegian Securities Trading Act section 5-12.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-09-25 12:15 CEST.